United States: US scientists has asserted that they have reduced some of the health advantages of exercise to a tablet form.
Although the new medication is still in its early phases of research and development, preliminary mouse studies suggest that it may activate a natural metabolic pathway that is often activated by physical activity.
The medication, SLU-PP-332, appears to increase muscular function, endurance, and fitness in mice when given daily; the animals don’t appear to have to exercise any more than they already do.
At the 2024 Spring meeting of the American Chemical Society, main investigator and Washington University scientist Bahaa Elgendy asserts that he and his team have achieved where others have failed.
For a few years now, researchers at Washington University in St. Louis and the University of Florida (UF) have been developing an estrogen-related receptors (ERR) medication. It is intended to focus on three distinct forms of ERR, an accomplishment never previously accomplished.
Inspired by their success, Elgendy and his associates have founded Pelago Pharmaceuticals, a new pharmaceutical business they hope would “launch this target’s clinical translatability.”
Elgendy and colleagues have demonstrated in previous studies that SLU-PP-332 administration to mice results in a rise in a kind of muscle fiber that is resistant to exhaustion in the body.
As a result, the rats’ endurance increases on treadmills, enabling them to run for up to 70 percent longer and 45 percent further than those who do not take the medication. This is most likely because their skeletal muscle cells are more adept at preserving their energy equilibrium.
Subsequent studies revealed that, while maintaining the same food intake and activity levels, mice given SLU-PP-332 twice a day for a month accumulated 10 times less fat than mice given no treatment.
POPULAR | Scientists discover fossil of 240mn years old Chinese dragon
